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Abstract: Over the recent years, several Re(i) organometallic compounds have been shown to be toxic
to various cancer cell lines. However, these compounds lacked sufficient selectivity towards cancer tis-
sues to be used as novel chemotherapeutic agents. In this study, we probe the potential of two known
N,N-bis(quinolinoyl) Re(i) tricarbonyl complex derivatives, namely Re(i) tricarbonyl [N,N-bis(quinolin-2-
ylmethyl)amino]-4-butane-1-amine () and Re(i) tricarbonyl [N,N-bis(quinolin-2-ylmethyl)amino]-5-valeric
acid (), as photodynamic therapy (PDT) photosensitizers. and proved to be excellent singlet oxygen gen-
erators in a lipophilic environment with quantum yields of about 75%. Furthermore, we envisaged to
improve the selectivity of via conjugation to two types of peptides, namely a nuclear localization signal
(NLS) and a derivative of the neuropeptide bombesin, to form and , respectively. Fluorescent microscopy
on cervical cancer cells (HeLa) showed that the conjugation of to significantly enhanced the compound’s
accumulation into the cell nucleus and more specifically into its nucleoli. Importantly, in view of PDT
applications, the cytotoxicity of the Re complexes and their bioconjugates increased significantly upon
light irradiation. In particular, was found to be at least 20-fold more toxic after light irradiation. DNA
photo-cleavage studies demonstrated that all compounds damaged DNA via singlet oxygen and, to a
minor extent, superoxide production.
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Schistosomiasis is a major human health problem, particu-
larly in rural, tropical regions of developing countries. Every
year, 280000 deaths are reported, mostly in sub-Saharan
Africa, and more than 207 million people are infected.[1] To
further emphasize the socioeconomic significance of this dis-
ease, experts consider schistosomiasis as one of the most
devastating parasitic diseases after malaria in tropical coun-
tries.[2] Currently, a racemic mixture of praziquantel (PZQ,
Scheme 1) is the frontline drug for treatment and control of
schistosomiasis. PZQ, which is believed to target the volt-
age-gated Ca2+ channels in the membrane of the parasite,
exhibits broad-spectrum anthelmintic activity against the
main species of Schistosoma.[3] However, reduced suscepti-
bility of Schistosoma mansoni (S. mansoni) to PZQ has been
reported recently.[4] This worrying evidence associated to the
known drawbacks of PZQ, that is, low metabolic stability in
vivo[5] and lack of activity against the juvenile stage of Schis-
tosoma,[3b] emphasizes the need for the rapid discovery of al-
ternative drugs to treat schistosomiasis. With this perspec-
tive, and concurrently with the investigations of the purely
organic modifications of the PZQ structure undertaken by
others,[6] our groups have recently initiated a program to de-
rivatize PZQ with organometallic moieties.[7] This strategy
was shown to be very successful in the development of anti-
cancer, antibacterial, and antimalarial compounds,[8] with
the ferrocenyl analogue of the antimalarial drug chloroquine
(CQ), namely ferroquine, being the best example. Ferro-
quine, which is licensed by the pharmaceutical company
Sanofi, was found to be active against CQ-resistant strains
of Plasmodium falciparum by different metal-specific modes
of action.[9] Furthermore, ruthenium half-sandwich com-
plexes were also tested for their anti-parasitic activity
against Trypanosoma cruzi (which is responsible for Chagas
disease), with promising results in vitro.[10]
In an initial study, we envisaged either replacing or modi-
fying the cyclohexyl moiety of PZQ with different ferrocen-
yl derivatives (Scheme 1, Strategies I and II). Using this
strategy, of eighteen ferrocenyl-PZQ derivatives made, only
two showed moderate anthelmintic activity against S. man-
soni in vitro.[7] Herein, we present an alternative strategy
that employs the organometallic derivatization on the aro-
matic part of PZQ (Scheme 1, strategy III). For this pur-
pose, we selected the {Cr(CO)3} moiety as the fragment to
be attached to PZQ for following reasons. First, the prepara-
tion of [(h6-arene)Cr(CO)3] derivatives is usually straightfor-
ward and the resulting compounds are, in most cases, air-
and water-stable. Second, we anticipated that the attach-
ment of this organometallic moiety may improve the physi-
cochemical properties of the parent drug (enhancement of
lipophilicity, increase of metabolic stability and/or alteration
of structural and electronic properties of the aromatic part
of PZQ). Worthy of note, different bioorganometallic com-
pounds containing the {Cr(CO)3} entity were shown earlier
to be useful in field of receptorology and more recently in
diverse areas of medicinal chemistry including as antimicro-
bial, anti-inflammatory, or antimalarial agents.[11] These find-
ings contrast to the common believe that all chromium com-
plexes are toxic. The toxicity of chromium complexes
mainly depends on the oxidation state of the metal center,
nature of the ligand, solubility, and the dosage provided. Im-
portantly, the CrIII salts that can be potentially formed by
light- or oxygen-induced oxidative decomposition of [(h6-
arene)Cr(CO)3] derivatives in solution are relatively less or
non-toxic compared to the highly toxic CrVI species.[11g,12] It
is also important to note that other “feared” metals, such as
arsenic, antimony, gold, silver, and bismuth, have been used
or are still currently being used in diverse forms in medi-
ACHTUNGTRENNUNGcines.[11g,13] One of the best examples is the arsenic-contain-
ing organometallic compound Salvarsan, which was used
against syphilis until the 1940s, before penicillin reached the
market.[8b,13a]
In this study, the antischistosomal effects of two [(h6-
PZQ)Cr(CO)3] (Cr-PZQ) derivatives (1 and 2 ; Scheme 2)
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Scheme 1. Structures of praziquantel (PZQ) and derivatives of PZQ with
organometallic moieties that were designed using three different strat-
egies.
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were investigated. These compounds were prepared in a
one-step procedure using commercially available PZQ
(Scheme 2). PZQ was heated with [Cr(CO)6] at 140 8C to
yield the diastereomeric mixture of 1 and 2 in 77% com-
bined yield (note that both 1 and 2 are racemates); 1 and 2
were found to be easily separable by silica-gel flash column
chromatography. After purification, the ratio between 1 and
2 was determined to be 65 and 35%, respectively. As ex-
pected, for both diastereomers, an upfield shift in the aro-
matic proton signals compared with that of PZQ was ob-
served in their 1H NMR spectrum (see the Supporting Infor-
mation). ESI-MS spectra as well as the elemental analysis
confirmed unambiguously the presence of the expected
compounds. The designation was facilitated by the determi-
nation of the X-ray single-crystal structure of 2. Compound
2 crystallized as a racemic mixture, and the ORTEP repre-
sentation of one of the enantiomers is presented in Figure 1.
The chromium tricarbonyl moiety is trans to the proton H18
linked to the chiral carbon C18. Furthermore, the structure
of 2 does not contain any unusual structural features.[11a]
Having the Cr-PZQ derivatives in hand, we first deter-
mined the distribution coefficients of 1 and 2 using the
“shake-flask” method. The presence of chromium in 1 and 2
allows their detection in the aqueous phase by atomic ab-
sorption spectroscopy (see experimental section in the Sup-
porting Information for further details). As expected, owing
to the presence of a {Cr(CO)3} moiety, the lipophilicity of
both 1 (logD7.4=3.49) and 2 (logD7.4=3.59) are significantly
higher than that of PZQ (logD7.4=2.66).
[14] The membrane
permeability is therefore expected to be higher for the Cr-
PZQ derivatives compared to that of PZQ. The in vitro an-
thelmintic potential of 1 and 2 was then tested against adult
S. mansoni, using PZQ as a control. Table 1 shows antischis-
tosomal effects in the nanomolar range for both 1 and 2.
These antischistosomal activities were comparable to that of
the parent drug PZQ (IC50=0.1 mm). The toxicity of 1 and 2
on mammalian cells was then assessed on the cervical
cancer (HeLa) and non-cancerous (MRC-5) cell lines
(Table 1). Both compounds were moderately cytotoxic to
HeLa cells but not toxic to MRC-5 cells. The high ratio
ACHTUNGTRENNUNG(>270) calculated as the highest activity of 1 and 2 on HeLa
cells (68.5 mm) divided by the anthelmintic activity of 1 and
2 (0.25 mm) is a good indication of the selectivity of 1 and 2
to schistosomes.
To exclude that the promising antischistosomal activities
of 1 and 2 achieved in vitro were not due to the release of
praziquantel, the stability of the Cr-PZQ derivatives in
water was assessed. For this purpose, 1 and 2 were dissolved
in a [D6]DMSO/D2O mixture and kept in the dark.
1H NMR
spectra were then studied at different time intervals, and the
presence of PZQ as a decomposition product of 1 and 2 was
assessed. Very little or no PZQ was detected after two days
(Supporting Information, Figures S1,S2); 1 was relatively
stable and only about 8% of PZQ was released after 27
days. By comparison, 2 was shown to decompose at a higher
rate (ca. 22% release in the same time). Furthermore, to
further confirm the results obtained with these NMR stud-
ies, the stabilities of the Cr-PZQ derivatives in human
plasma were also evaluated. Consistent with findings for the
parent drug PZQ,[7] no significant change was observed
either for the UV traces or the ratio between diazepam (in-
ternal standard) and 1 or 2 (Figure 2; Supporting Informa-
tion, Figure S3,S4) up to 24 h, suggesting that the Cr-PZQ
derivatives are relatively stable in biological medium such
as serum. These results infer that chromium tricarbonyl
complexes are stable and the in vitro activity was exhibited
by the Cr-PZQ derivatives but not by the released PZQ.
In conclusion, we have demonstrated that two easy-to-
prepare chromium tricarbonyl PZQ derivatives achieve an
impressive antischistosomal effect (nanomolar range) on
adult S. mansoni in vitro. Importantly, these compounds
Scheme 2. Synthesis of Cr-PZQ derivatives 1 and 2. Note that all of the
compounds are racemic. Reaction conditions: i) [Cr(CO)6], Bu2O, THF,
140 8C.
Figure 1. X-ray single-crystal structure of 2 (only one enantiomer is
shown). Ellipsoids are set at 50% probability; hydrogen atoms (except
H18) are omitted for clarity.
Table 1. In vitro activity of Cr-PZQ derivatives against adult S. mansoni
and cytotoxicity against HeLa and MRC-5 cells.
Compound Anthelmintic activity
against S. mansoni (mm)
r* [a] IC50 values (mm)
HeLa MRC-5
1 0.25 0.96 68.53.0 >100
2 0.27 0.97 81.41.5 >100
PZQ 0.10 0.99 >100 >100
[a] r* is the goodness of fit, which is required to be 0.85.[15]
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were shown to be safe when tested using two distinct cell
lines and had remarkable selectivity for the adult stage of S.
mansoni that lives in the portal and mesenteric vein system
of the human host.[16] Moreover, the stability of both com-
pounds in human serum was confirmed by LC-MS measure-
ments. No significant decomposition was observed when the
compounds were incubated in human plasma at 37 8C for
24 h. These findings therefore strongly contrast with the cur-
rent belief that organometallic compounds, and more impor-
tantly, chromium tricarbonyl complexes, are unstable and/or
cytotoxic. The results presented herein is another contribu-
tion to the booming field of research of medicinal organo-
metallic chemistry[17] and pave the way for a systematic in-
vestigation of the structure-activity relationship of organo-
metallic derivatives of PZQ as well as in vivo testing of such
compounds.
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Figure 2. Ratio [%] of Cr-PZQ derivatives 1 and 2 to diazepam (internal
standard) at different incubation times in human plasma.
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